

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No.: 03-334-A)

In re Application of:)	
Van Zandt et al.)	Before the Examiner:
)	Lambkin, Deborah C.
Serial No.: 10/824,057)	
)	
Filed: April 14, 2004)	Art Unit: 1626
)	
For: Substituted Phenylalkanoic)	Confirmation No. 8007
acids for the Treatment of)	
Diabetes)	


RESPONSE TO THE RESTRICTION REQUIREMENT
MAILED JUNE 14, 2007

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Restriction Requirement mailed June 14, 2007, the Applicants elect Group VII for prosecution. Group VII is identified by the Examiner as being drawn to "compounds, compositions and methods of formula I wherein R2 is a non-heteroaryl containing moiety, A is pyrazoyl or dihydropyrazolyl and Q is non-het."

To comply with the requirement for a species election, the Applicants further elect the following compound: N-({4-[3-(4-chlorophenyl)-5-(4-pentylphenyl)-1H-pyrazol-1-yl]phenyl}sulfonyl)-N-methylphenylalanine. This species is Compound no. 43, found on page 92 of the specification. This compound can be represented by the following structural formula:



The claims that read on this species are claims 1-12, and 20-22.

The Applicants invite the Examiner to contact the Applicants' undersigned representative at (312) 913-2136 if the Examiner believes that this would expedite prosecution of this application.

Respectfully submitted,

September 14, 2007

By: /Steven J. Sarussi/

Steven J. Sarussi
Reg. No. 32784

McDonnell Boehnen
Hulbert & Berghoff LLP
300 S. Wacker Drive
Chicago, IL 60606
(312) 913-2136